Management of a patient with a malignant cutaneous tumor

Journal of Wound, Ostomy and Continence Nursing

Volumn 30, Issue 4, 2003, Pages 231-236

  Woodward, Linda ^a   Haisfield Wolfe, Mary Ellen ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; METRONIDAZOLE;

AGED; ARTICLE; BANDAGE; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPRESSION THERAPY; DEBRIDEMENT; HUMAN; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; NECROSIS; ODOR CONTROL; WOUND CARE; WOUND DRESSING;

EID: 0043124589     PISSN: 10715754     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjw.2003.138     Document Type: Article

References (17)

1. Holleb A, Fink N, Murphy G. American Cancer Society textbook of clinical oncology. Atlanta, GA: American Cancer Society; 1991. p. 359-74.
2. Groenwald S, Frogge M, Goodman M, Yarbro C. Cancer nursing: principles and practice. 3rd ed. Boston, MA: Jones and Bartlett; 1993: p. 878-900.
3. Brennan MF, Alektier KM, Maki R. Sarcomas of soft tissue and bone. In: De Vita V, Hellman S, Rosenberg S, editors. Cancer principles and oncology practice. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1888-9.
4. Oda Y, Tamiya S, Oshiro Y, Hactianda Y, Kinukawa N, Iwamato Y, et al. Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathology Int 2002;52:595-606.
5. Stedman's Medical Dictionary (27th Ed.). Baltimore: Lippincott, Williams & Wilkins; 2000.
6. Piasecki P. Bone and soft tissue sarcoma. In: Yarbro CH, Goodman M, Hansen-Frogge M, Groenwald S, editors. Boston: Jones & Bartlett; 2000.
7. Ueda T, Araki N, Mano M, Myoui A, Joyama S, Ishiguro S, et al. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone. J Clin Pathol 2002;55:853-8.
8. Naylor W. World wide wounds,part 1: symptom control in the management of fungating wounds [online] 2002 [accessed 2002 Mar 5]. Available from: URL: http://www.worldwidewounds.com/2002/march/.../ Symptoms-Control-Fungating-Wounds.html
9. Collier M. Management of patients with fungating wounds. Nurs Stand 2000;29:47-51.
10. Barton P, Parslow N. Caring for oncology wounds: management guidelines. Montreal: Convatec Division of Bristol Myers Squibb; 1998. p. 1-2, 4-5, 16-33.
11. Carville K. Caring for cancerous wounds in the community. J Wound Care 1995;4:68-9.
12. Grocott P, Dip N. The palliative management of fungating malignant wounds. J Wound Care 1995;4:240-2.
13. Lawrence JC, Lilly HA, Kidson A. Malodour and dressings containing active charcoal. Proceedings of the 2nd European Conference on Advances in Wound Management; 1992 Oct 20-23; Harrogate, United Kingdom. p. 73-4.
14. Sussman C. Wound healing biology and chronic healing. In: Sussman C, Bates-Jensen BM, editors. Wound care. Gaithersburg (MD): Aspen; 1998. p. 221-2.
15. Haisfield-Wolfe ME, Rund C. Malignant cutaneous wounds: developing education for hospice, oncology and wound care nurses. Int J Palliative Care 2002;8:57-66.
16. Gates JL. Palliative care: a wound care option. In: Krasner D, Kane D, editors. Chronic wound care. 2nd ed. Wayne (PA): HMP; 1997. p. 333-5.
17. Bauer NA, Hon BA, Comm B. The palliative wound care option. Poster presentation at 32nd Annual Conference of The Wound, Ostomy and Continence Society; 2000 June 4-8; Toronto, Ontario, Canada.